Table 3.
Summary of framework domains
| Domains | Pharmaceutical management system framework | Pharmaceutical management framework | Medical products building block, WHO health systems framework | Control knobs framework | Conceptual framework of access to medicines from a health systems perspective | PSS framework | |
|---|---|---|---|---|---|---|---|
| RPM Plus 2005, Miralles 2010 | MSH 2012 | WHO 2007, WHO 2010b | Roberts and Reich 2011 | Bigdeli et al. 2013 | SIAPS 2013 | ||
| Goals | Access (accessibility, availability, acceptability, affordability, quality) | ▪ | ▪ | ▪ | ▪ | ▪ | ▪ |
| Use (appropriate, rational) | ▪ | ▪ | ▪ | ▪ | ▪ | ||
| Contribute to health outcomes/status | ▪ | ▪ | ▪ | ▪ | ▪ | ||
| Coverage | ▪ | ▪ | |||||
| Efficiency | ▪ | ▪ | ▪ | ||||
| Social and Financial protection | ▪ | ▪ | |||||
| Responsiveness | ▪ | ||||||
| Satisfaction | ▪ | ||||||
| Products accessed and used | Medicines | ▪ | ▪ | ▪ | ▪ | ▪ | ▪ |
| Pharmaceutical products/pharmaceuticals | ▪ | ▪ | ▪ | ▪ | |||
| Medical products | ▪ | ▪ | |||||
| Vaccines | ▪ | ||||||
| Health technologies | ▪ | ||||||
| Pharmaceutical services | ▪ | ▪ | ▪ | ▪ | |||
| Characteristics of products accessed and used | Quality | ▪ | ▪ | ▪ | ▪ | ▪ | ▪ |
| Essential | ▪ | ||||||
| Safe/safety | ▪ | ▪ | ▪ | ▪ | |||
| Effective (efficacy) | ▪ | ▪ | ▪ | ▪ | |||
| Cost-effective | ▪ | ▪ | |||||
| Qualities associated with access and use | Quality | ▪ | ▪ | ▪ | ▪ | ▪ | |
| Safe/safety | ▪ | ||||||
| Effective | ▪ | ▪ | ▪ | ||||
| Cost-effective | ▪ | ||||||
| Scientifically sound | ▪ | ||||||
| Overarching principles | Equity | ▪ | ▪ | ▪ | ▪ | ▪ | |
| Timeliness | ▪ | ||||||
| Human rights | ▪ | ||||||
| Stakeholders | Structures/institutions/organizations | ▪ | ▪ | ||||
| Individuals/people | ▪ | ▪ | |||||
| Government | ▪ | ||||||
| Providers | ▪ | ||||||
| Communities and households | ▪ | ▪ | ▪ | ||||
| Public sector | ▪ | ||||||
| Private sector | ▪ | ||||||
| International, national, subnational, and local | ▪ | ||||||
| Functions (subsystems) | Selection | ▪ | ▪ | ||||
| Procurement (procurement and importing) | ▪ | ▪ | ▪ | ||||
| Distribution (supply chain) | ▪ | ▪ | ▪ | ||||
| Use (dispensing; sales) | ▪ | ▪ | ▪ | ||||
| Research and development (including clinical trials) | ▪ | ||||||
| Regulation (including registration and licensing of individuals and facilities) | ▪ | ||||||
| Manufacturing and packaging | ▪ | ||||||
| System Components | Service delivery | ▪ | ▪ | ▪ | ▪ | ||
| (Leadership and) governance | ▪ | ▪ | ▪ | ▪ | ▪ | ||
| Policies, law, and regulation (supported by good governance) | ▪ | ▪ | ▪ | ||||
| Resources (management support systems/inputs): | |||||||
| Medical products, medicines, vaccines, health technologies | ▪ | ▪ | ▪ | ▪ | |||
| Human resources/health workforce | ▪ | ▪ | ▪ | ▪ | ▪ | ||
| Information | ▪ | ▪ | ▪ | ▪ | ▪ | ||
| Financing (pricing; price setting/negotiation) | ▪ | ▪ | ▪ | ▪ | ▪ | ||
| Infrastructure | ▪ | ||||||
| Organization | ▪ | ||||||
| Context | Market forces | ▪ | |||||
| Innovation | ▪ | ||||||
| Transparency | ▪ | ||||||
| Donor’s agenda and funding | ▪ | ||||||